MarketPulse

clinical trial protocol

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Nektar Therapeutics Hit With Securities Lawsuit Over Misleading Trial Disclosures

Rosen Law Firm alerts $NKTR investors of May 5, 2026 deadline to join securities class action over alleged false statements regarding REZOLVE-AA trial enrollment protocols.
NKTRsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Nektar Therapeutics Hit With Class Action Over Alleged Trial Misstatements

Class action filed against Nektar Therapeutics alleging false trial statements regarding REZOLVE-AA enrollment. Lead plaintiff deadline: May 5, 2026.
NKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Nektar Therapeutics Faces Class Action Over Misleading Trial Statements

Class action lawsuit filed against Nektar Therapeutics alleging executives made false statements about REZOLVE-AA trial enrollment, claiming protocol violations negatively impacted results.
NKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nektar Therapeutics Faces Class Action Over Misleading Trial Data Claims

Class action lawsuit filed against $NKTX alleging executives made false statements about REZOLVE-AA trial enrollment protocols, potentially harming investor value.
NKTRsecurities fraudclass action lawsuit